Honored to start my first day as the new Editor in Chief of the European Journal of Preventive Cardiology. Thank you to all at #ESC and #EAPC for their trust. Kudos to Massimo Massimo Piepoli #EJPC & his editors who brought up the Journal at such level. Will try my best with the new team.🤞

Must-read review in the latest issue of The Lancet on mechanisms and management of valvular heart disease sciencedirect.com/science/articl… The Lancet

From a meta-analysis of 5 studies, #TEER with the #MitraClip system appears to be equally safe and effective in patients with atrial FMR and ventricular FMR bit.ly/3xdZ4Bn

#JACC #vhdMR #Cardiology #CardioTwitter Gregg W. Stone MD

This study focused on the impact of the timing of bioprosthetic valve fracture (BVF) on the long-term outcomes of THVs, specifically the ACURATE neo and the 23 mm SAPIEN 3, deployed in 21 mm Mitroflow surgical valves. Results showed that BVF performed after ViV TAVI presented

Secondary mitral regurgitation (SMR) is a heterogeneous disease entity presenting with different clinical phenotypes. Differentiation of SMR phenotypes (aSMR vs vSMR) and their subentities might facilitate our understanding of treatment response to medial and interventional SMR

In mitral regurgitation, temporal variation of MR flow has been considered an important reason for inaccurate MR grading.

Are mitral valve prolapse and disjunction players in idiopathic ventricular fibrillation? Eivind Westrum Aabel, MD ProCardioSFI European Society of Cardiology Journals
Cardiac arrest, MAD and MVP - Where there is smoke, there is a fire academic.oup.com/ehjcimaging/ar…

Prosthesis-patient mismatch post-SAVR: FREE for 50 days: bit.ly/PPM_SAVR
See also: bit.ly/SAVR_PPM_Predi… and bit.ly/PPM_PARTNER2 Philippe Pibarot Vinod Thourani Omar Khalique Labo Dr Clavel Julien Ternacle Amr Abbas American College of Cardiology European Society of Cardiology

This multicenter, observational, #JACCINT study of 147 pts who underwent #TTVR screening, reported screening failure of 74%. This was primarily driven by large tricuspid annular diameter. Pts who underwent TTVR had superior TR reduction & symptom alleviation compared to bailout

Transcatheter treatment of the tricuspid valve: current status and perspectives. A State-of-the-Art Review just published in #EHJ
European Society of Cardiology European Society of Cardiology Journals #CardioTwitter francesco maisano Philipp Lurz

academic.oup.com/eurheartj/adva…

Establishment of #hiPSC differentiation into functional heart valve endothelial like cells #hiVECs & valve interstitial like cells #hiVICs & elucidation of the differentiation trajectory and transcriptional dynamics that mediate the differentiation ahajournals.org/doi/10.1161/CI…

Shortening in-hospital stay after transcatheter aortic valve implantation: a déjà vu in percutaneous interventions. Read the latest Editorial in EHJ:
academic.oup.com/eurheartj/adva…

#TAVI #cardiotwitter European Society of Cardiology Journals European Society of Cardiology

#THT2024 In the context of tricuspid regurgitation related to a pacemaker lead, there's always a risk in removing the lead. However, leaving a lead in place can also pose risks, especially in the context of endocarditis. It's possible to implant a TTVI with a lead in place.

The new issue of #JACCIMG is out!

In aortic stenosis, #echofirst LV mechanical dispersion (MD) provides prognostic value over global longitudinal strain (GLS). MD≥68ms and GLS≥-15% represent a high-risk #cvVHD subgroup. bit.ly/3Im1XSX

#vhdAS Marechaux

This study finds that in atrial functional mitral regurgitation (AFMR) patients, optimal MR reduction (≤1+) post-TEER significantly improves clinical outcomes, while an elevated MPG (≥5 mmHg) increases risks. These results highlight the importance of achieving optimal MR

Wow great #Echofirst case from 🇮🇳 with Acute rheumatic fever with an AML mass consistent with hypertrophic Aschoff nodule, with the presence of anitschkow cells on path. Patient s/p MVR + steroids! 😮 😮 😮
#ACCImaging #CVimaging

Limitations of NOTION: TAVR with SEV of first generation: SAVR valves: 35% were Trifecta or Mitroflow; major survivorship bias (only 35% of patients still alive at 10 years), no echo corelab for adjudication of SVD.

NOTION 10 years: Similar rates of stroke mortality and all-cause BVF so valve durability in TAVR vs. SAVR. Reassuring results but not definitive conclusion.
Transcatheter or surgical aortic valve implantation: 10-year outcomes of the NOTION trial academic.oup.com/eurheartj/arti…

La SFC témoigne de sa tristesse et de sa douleur mais aussi de son immense fierté d’avoir compté parmi elle le Pr Alain Cribier. Ses qualités humaines doivent continuer à nous animer et sa carrière doit être un exemple pour toute notre communauté !

🫀 Severe Primary MR - Carpentier IIIa - 55 yo man
❓ What is the underlying cause?

#echofirst #3decho #CardioTwitter #Cardiology